Achilles Therapeutics Plc ADR [ACHL] stock is trading at $1.39, saw in change for the day. Until recently, the best way to gauge how the stock has performed was to look at its short-term value.
From an analyst’s perspective:
Achilles Therapeutics Plc ADR [NASDAQ: ACHL] stock has seen the most recent analyst activity on April 05, 2024, when Piper Sandler downgraded its rating to a Neutral and also revised its price target to $2 from $8. Previously, Piper Sandler started tracking the stock with Overweight rating on April 26, 2021, and set its price target to $25. On April 26, 2021, Oppenheimer initiated with a Outperform rating and assigned a price target of $23 on the stock. JP Morgan started tracking the stock assigning a Underweight rating and suggested a price target of $11 on April 26, 2021. Chardan Capital Markets initiated its recommendation with a Buy and recommended $27 as its price target on April 26, 2021. BofA Securities started tracking with a Buy rating for this stock on April 26, 2021, and assigned it a price target of $20.
Achilles Therapeutics Plc ADR [ACHL] stock has fluctuated between $0.63 and $1.41 over the past year. Currently, Wall Street analysts expect the stock to reach $2 within the next 12 months. Achilles Therapeutics Plc ADR [NASDAQ: ACHL] shares were valued at $1.39 at the most recent close of the market. An investor can expect a potential return of 43.88% based on the average ACHL price forecast.
Analyzing the ACHL fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -0.55 and Total Capital is -0.69. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3783 points at the first support level, and at 1.3667 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4033, and for the 2nd resistance point, it is at 1.4167.
Ratios To Look Out For
For context, Achilles Therapeutics Plc ADR’s Current Ratio is 6.04. As well, the Quick Ratio is 6.04, while the Cash Ratio is 4.66.
Transactions by insiders
Recent insider trading involved Coutts Robert William, Officer, that happened on Mar 03 ’25 when 4168.0 shares were purchased. Director, Ali Iraj completed a deal on Mar 03 ’25 to buy 9376.0 shares. Meanwhile, Officer Coutts Robert William bought 334.0 shares on Feb 13 ’25.
